ONWARD Medical

Netherlands - EindhovenBiotechnology1 H-1B visas (FY2023)

Focus: ONWARD Medical is a Netherlands-based biotechnology company specializing in ARCex non-invasive spinal cord stimulation technology for neurology and musculoskeletal indications. The company operates in a focused therapeutic niche with a proprietary neuromodulation platform.

Neurology Musculoskeletal

Profile data last refreshed 22h ago · AI intelligence enriched 1w ago

Open Jobs

About ONWARD Medical

AI assessmentNot Hiring

No open roles listed right now. Follow ONWARD Medical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Task Practice combined with Transcutaneous Spinal Cord Stimulation

Spinal Cord Injury Cervical

N/A

Clinical Trials (1)

NCT06494020Task Practice and Spinal Cord Stimulation

N/A

Help build intelligence for ONWARD Medical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneering position in non-invasive spinal cord stimulation, a high-growth neuromodulation segment with significant unmet clinical need
European headquarters in Eindhoven provides access to strong academic neuroscience research ecosystem and medical device innovation clusters
Focused pipeline in high-value therapeutic areas (neurology, musculoskeletal) with potential for rapid market expansion post-approval

Watch Out For

Currently zero active job openings signals either full staffing or potential hiring freeze, limiting near-term career entry points
Incomplete financial and pipeline data suggests either early-stage development, private status, or limited public disclosure—reducing visibility into company trajectory and stability

Generated by Claude from ONWARD Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

LIFT System

Chronic Spinal Cord Injury

N/A

Clinical Trials (1)

NCT04697472The Up-LIFT Study of Non-Invasive ARC Therapy for Spinal Cord Injury

N/A

transcutaneous Spinal Cord Stimulation

Tetraplegia

N/A

Clinical Trials (1)

NCT06140706Feasibility of Home Based Transcutaneous Spinal Cord Stimulation for Persons With SCI

N/A

LIFT System

Chronic Spinal Cord Injury

N/A

Clinical Trials (1)

NCT05284201LIFT Home Study of Non-Invasive ARC Therapy for Spinal Cord Injury

N/A

ARC-IM Thoracic System implantation

Spinal Cord Injury

N/A

Clinical Trials (1)

NCT05941819ARC Therapy to Restore Hemodynamic Stability and Trunk Control in People With Spinal Cord Injury

N/A

ARC-IM System Implantation

Spinal Cord Injuries

N/A

Clinical Trials (1)

NCT07147296ARC-IM System to Manage Symptomatic Blood Pressure Instability Secondary to Chronic Spinal Cord Injury

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 6 clinical trials

H-1B (2023): 1 approval

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub